Europe Bladder Cancer Therapeutics Diagnostics Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Bladder cancer remains one of the more common urological malignancies in Europe, with incidence rising as the population ages and exposure histories to smoking and occupational carcinogens continue to feed new diagnoses. The combined therapeutics and diagnostics market in the region is currently worth about USD 0.86 billion and is on track to grow at a compound annual rate near 8.19% through 2030. Diagnostic procedures such as cystoscopy, biopsy, urine cytology, and molecular biomarker assays account for a significant share of current revenue, while drug therapy for muscle-invasive and metastatic disease represents the fastest-growing slice.

• •European market valued at approximately USD 0.86 billion in 2025 with an ~8.19% CAGR through 2030
• •Urothelial carcinoma is the dominant disease subtype covered, with non-muscle-invasive bladder cancer (NMIBC) representing the largest patient pool
• •Diagnostics and therapeutics are reported as a combined market, with diagnostic procedures currently contributing the larger revenue share

Rising incidence of bladder cancer across Western and Eastern Europe is the single biggest underlying demand driver, supported by demographic aging and better disease awareness among primary-care physicians. Parallel advances in treatment, including immune checkpoint inhibitors, antibody-drug conjugates such as enfortumab vedotin, and targeted therapies for FGFR-altered tumors, are expanding the addressable drug market. On the diagnostic side, adoption of urine-based biomarker tests, next-generation sequencing of tumors, and improved imaging modalities is shortening time to diagnosis and enabling recurrence monitoring.

• •Aging European population and persistent smoking prevalence are lifting bladder cancer incidence
• •Approval and uptake of immunotherapies and ADCs are reshaping the treatment landscape for advanced disease
• •Improved diagnostic technologies, including biomarkers and molecular testing, are expanding screening and surveillance volumes

The market splits into a therapeutics segment (chemotherapy, intravesical therapy such as Bacillus Calmette-Guérin, immunotherapy, and targeted therapy) and a diagnostics segment (cystoscopy, biopsy, urine cytology, biomarker assays, and imaging). Within Europe, Western European countries including Germany, France, the United Kingdom, Italy, and Spain represent the largest national markets, while Central and Eastern European countries are growing faster from a lower base as healthcare infrastructure improves. NMIBC accounts for roughly three-quarters of incident cases and dominates both diagnostic and intravesical treatment revenue.

• •Therapeutics segment covers chemotherapy, intravesical BCG and chemotherapy, immunotherapy, and targeted agents
• •Diagnostics segment is led by cystoscopy and biopsy, with urine biomarkers and molecular tests growing fastest
• •Western Europe leads current revenue while Central and Eastern Europe show the highest growth rates

What are the recent trends and outlook?

The European bladder cancer market is expected to continue outpacing overall oncology growth, supported by an expanding immunotherapy and ADC pipeline and earlier use of biomarker-guided treatment selection. Adoption of liquid biopsy and urine-based molecular testing is likely to reduce reliance on invasive cystoscopy for surveillance, while value-based healthcare initiatives in countries such as the UK, Germany, and France are pushing providers toward faster, more accurate diagnostics. Through 2030 and beyond, the combined therapeutics and diagnostics market is on a clear path toward materially higher annual revenue, with innovation rather than incidence alone driving most incremental growth.

• •Pipeline expansion in ADCs, bispecific antibodies, and FGFR-targeted agents is expected to widen treatment options
• •Liquid biopsy and urine-based molecular diagnostics are gaining traction for surveillance and early detection
• •Europe-wide initiatives on early cancer detection and value-based care are expected to reinforce market expansion through 2030